enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
enVVeno Medical ended Q1 2026 with $24.9 million in cash and investments, providing a runway into Q3 2027 to support the TAVVE pivotal study. The company achieved a landmark FDA IDE approval for the TAVVE study, the first-ever FDA approval for a pivotal study of a non-surgical replacement venous valve.
Key figures
- Revenue
- 0
- Guidance
- Cash resources sufficient to fund operations into Q3 2027; cash burn rate expected to increase to approx $4M-$5M per quarter in 2026 due to TAVVE study initiation
- Revenue Yoy
- 0
- Net loss
- 3800000
- Cash burn
- 3300000
- Cash and investments
- 24900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.